<DOC>
	<DOCNO>NCT01986140</DOCNO>
	<brief_summary>Determine Orbis Paxman Hair Loss Prevention System safe effective reduce chemotherapy-induced alopecia woman breast cancer undergo neoadjuvant adjuvant chemotherapy .</brief_summary>
	<brief_title>Scalp Cooling Prevent Chemo-induced Hair Loss</brief_title>
	<detailed_description>Cooling scalp chemotherapy may help reduce chance lose hair treatment . The investigator hop use PAXMAN Orbis Scalp Cooling Device may stop patient undergo chemotherapy lose hair .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>New diagnosis breast cancer stage 12 Planning undergo neoadjuvant adjuvant chemotherapy curative intent Chemotherapy must plan least 4 cycle fulldose anthracycline taxane base chemotherapy regimen , Defined one follow regimen : Adriamycin 60mg/m2 cyclophosphamide 600mg/m2 Epirubicin 90100mg/m2 cyclophosphamide 600mg/m2 Paclitaxel 80mg90/m2 weekly ( every three week constitute cycle ) , 175 mg/m2 every 23 week single agent Docetaxel 100mg/m2 single agent Docetaxel 75mg/m2 cyclophosphamide 600mg/m2 Docetaxel 75mg/m2 carboplatin AUC 6 trastuzumab standard dose Trastuzumab standard dose allow combination taxane base chemotherapy Administration chemotherapy dose dense schedule allow clinically indicate . Stage 3 4 breast cancer concurrent malignancy include hematological malignancy ( i.e . leukemia lymphoma ) Baseline alopecia ( define CTCAE v4.0 grade &gt; 0 , see appendix B CTCAE v4.0 scale ) Subjects cold agglutinin disease cold urticaria Subjects schedule bone marrow ablation chemotherapy Subjects receive chemotherapy concurrent anthracycline taxane ( AT TAC ) Male gender</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Alopecia</keyword>
	<keyword>Scalp</keyword>
	<keyword>Cooling</keyword>
</DOC>